Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$13.65 - $21.8 $137 Million - $218 Million
-10,000,000 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$24.23 - $30.93 $124 Million - $158 Million
-5,117,460 Reduced 33.85%
10,000,000 $304 Million
Q3 2017

Nov 14, 2017

BUY
$23.35 - $29.24 $353 Million - $442 Million
15,117,460
15,117,460 $366 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.5B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Matrix Capital Management Company, LP Portfolio

Follow Matrix Capital Management Company, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Matrix Capital Management Company, LP, based on Form 13F filings with the SEC.

News

Stay updated on Matrix Capital Management Company, LP with notifications on news.